🔥 Hot off the press from @efisg_escmid! #Candida endocarditis — rare, deadly (⚰️ up to 49% mortality), and still full of challenges: 🫀 Imaging 💊 Antifungals 😷 Surgery Read the latest review 👇 https://t.co/ql2Jv0hBSw #IDTwitter #FungalInfections

#EFISG fungal recommendations for #EFISGbroadcaster #ESCMID2025 #ESCMIDGlobal2025 @efisg_escmid

ESCMID is celebrating the International Day for Women and Girls in Science with two leaders in our Society. Giulia De Angelis and Angela Huttner have spoken with us about the importance of this day and you can read here: https://t.co/7Uz5POqdEq #WomenInScience #WomenInSTEM

🚨🌟 EFISG Webinar Alert! 🌟🚨 🗓️February 18th, 15:00 CET 🩺 Invasive mould infections in conflict zones 🌍 1⃣ IFI in conflict zones 2⃣ Managing IFI in limited-resource settings 3⃣ Preventing IFI: Lessons from field hospitals 💻 Register now for FREE! https://t.co/RPkf1YPF6h

Posaconazole for Prevention of COVID‐19‐Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients: A European Multicentre Case–Control Study @jprattes @danieleroberto4 @GangneuxJp @ProfMBassetti @FReizine @eller_philipp @RobertK05753862 https://t.co/V3clIUSOKg

Important increase of #azoleresistance in Belgium the last years! With 9.7% especially in combination with a high incidence of mould coinfections (12%) reason to be careful with the clinical approach towards our frail patients. #aspergillosis @lagrou_katrien @johanM94028778

#MucoralesPCR diagnosing mucormycosis and detecting mould coinfections much earlier than conventional methods, AND impacting the outcome with increased survival since introduction of the MucorPCR in France in 2015. No reason (not even financial) to not make the test available!

A fantastic collaboration with @SeldeslachtsL, @GreVVel and Joost Wauters uncovering the immunological mechanisms underlying IAPA

😷We need new antifungal strategies. 🧪But, recruitment in the (pragmatic) #HOVON502 study looking at #antifungal combination was difficult. 🍄Adding also low IA related mortality superiority trials seem unrealistic… @bjarijn @sammy_hgns @johanM94028778 https://t.co/p0UBFerlfu

😷 Host is key once more in our fight against fungal infections! 🦠 Excessive influenza-induced IFN-γ impaired the Th17 immune response against aspergillosis in IAPA murine model. 💊 Is targeting this pathway the future? @SeldeslachtsL @GreVVel

@CMIJournal #RCT proposal to test if 10-day #antifungal treatment for #candidemia is as effective as the 14-day standard. This could improve outcomes 📈, reduce resistance 🛡️, and lower healthcare costs 💰. Stay tuned! 👉 https://t.co/ETFuZAF1WO

🌍Great to see new publications coming from LMICs. 🍄Considerations after the 2nd International Collaborative Mycology Conference. 🧠The recommendations set a valuable example for other (LMI)countries! 📚🦠 https://t.co/1glwNOrPLe

🇩🇰Azole resistant Aspergillus fumigatus was found in 20% of the 366 environmental samples taken in Denmark (4.2% of all 4,538 isolates were azole resistant). ‼️ Dual use of azoles in clinical medicine and for crop protection challenges patient management! #aspergillosis #fungi

Feeling so honored, what a team! Let’s go! 🍄

🔔ORAL amphotericin B formulation (MAT2203)🔔Compassionate use in 5 cases (Rhodotorula, Candida krusei, Fusarium² and Histoplasma) -> in an area of azole resistance, coinfections and increase of non-Aspergillus mould infections something to keep an eye on.

🆕📰 Risk factors and outcome associated with #fungal 🍄 infections in patients with severe #burn injury 🔥 → Our 10 year IFI-BURN from @HopSaintLouis study with @EDudoignon just out in @CIDjournal Stay tuned, more to come… ! In long 👉 https://t.co/yTJPXA9DAA In short👇

Academic publishing: Scientists submit their work (often done in unpaid time) Reviewers review it - for free Then - the journal then charges people to read it or charges the *authors* ENORMOUS open access fees And the few staff they do pay? They pay poorly What a scam!!

😷The group of immunocompromised patients we are currently treating is evolving in its complexity. 🍄This shift results in more difficult presentations of mold infections, posing significant diagnostic and therapeutic challenges. ⚕️Interesting considerations on bIMI! #IDtwitter

💭CS on ICU are only truly indicated in very specific situations, and very debatable in many others! So not just a rescue for every very sick patient. 💊Risk of infections is related to the (cumulative) dose. Define net immune status of your patient, in its specific environment.